[go: up one dir, main page]

WO1998042650A3 - Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose - Google Patents

Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose Download PDF

Info

Publication number
WO1998042650A3
WO1998042650A3 PCT/US1998/005455 US9805455W WO9842650A3 WO 1998042650 A3 WO1998042650 A3 WO 1998042650A3 US 9805455 W US9805455 W US 9805455W WO 9842650 A3 WO9842650 A3 WO 9842650A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
leukotriene antagonists
treating cystic
antagonists useful
leukotriene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/005455
Other languages
English (en)
Other versions
WO1998042650A2 (fr
Inventor
Jerome H Fleisch
William T Jackson
Jason S Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU67647/98A priority Critical patent/AU6764798A/en
Publication of WO1998042650A2 publication Critical patent/WO1998042650A2/fr
Publication of WO1998042650A3 publication Critical patent/WO1998042650A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés de traitement ou d'inhibition des symptômes de mucoviscidose consistant à administrer, à un mammifère qui en a besoin, une quantité efficace d'un composé présentant une activité d'antagoniste de leucotriène B4.
PCT/US1998/005455 1997-03-21 1998-03-19 Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose Ceased WO1998042650A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67647/98A AU6764798A (en) 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4087097P 1997-03-21 1997-03-21
US60/040,870 1997-03-21

Publications (2)

Publication Number Publication Date
WO1998042650A2 WO1998042650A2 (fr) 1998-10-01
WO1998042650A3 true WO1998042650A3 (fr) 1998-12-23

Family

ID=21913422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005455 Ceased WO1998042650A2 (fr) 1997-03-21 1998-03-19 Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose

Country Status (2)

Country Link
AU (1) AU6764798A (fr)
WO (1) WO1998042650A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127882A1 (fr) 2000-01-25 2001-08-29 Pfizer Products Inc. Composés tétrazoliques comme ligands du récepteur thyroid
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP2080751A4 (fr) 2006-10-12 2011-06-22 Inst Med Molecular Design Inc Dérivé d'acide carboxylique
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
US5552441A (en) * 1992-12-10 1996-09-03 Eli Lilly And Company Leukotriene B4 antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
US5552441A (en) * 1992-12-10 1996-09-03 Eli Lilly And Company Leukotriene B4 antagonists
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5563164A (en) * 1993-12-23 1996-10-08 Eli Lilly And Company Phospholipase A2 inhibitors
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors

Also Published As

Publication number Publication date
AU6764798A (en) 1998-10-20
WO1998042650A2 (fr) 1998-10-01

Similar Documents

Publication Publication Date Title
MY121008A (en) Combination therapy comprising atorvastatin and an antihypertensive agent.
HUP0004412A3 (en) Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
HK1038755A1 (zh) Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
CA2311356A1 (fr) Procede pour le traitement de la maladie d'alzheimer
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
WO2001015678A3 (fr) Utilisation topique d'agonistes des kappa opioides afin de traiter les douleurs oculaires
PL336290A1 (en) Sulphonamides for treating endothelin-involving disorders
WO2001036365A3 (fr) Antagonistes recepteurs thyroidiens pour le traitement d'affections cardiaques et metaboliques
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
WO2004050030A3 (fr) Agents anti-drepanocytaire
ID20637A (id) Metode untuk menghambat pembentukan sulfida biogenik
EP0742010A3 (fr) Benzoquinolin-3-ones pour inhiber la perte osseuse
WO1999005096A3 (fr) Inhibiteurs d'urokinase
WO2000077206A3 (fr) Promoteur du gene de la myostatine et methode pouvant inhiber l'activation dudit promoteur
CA2378613A1 (fr) Antagonistes selectifs du recepteur iglur5 utilises dans le traitement de la migraine
WO2000061069A3 (fr) Procedes et compositions pour le traitement de l'hyperlipidemie
ZA9811507B (en) Combination effective for the treatment of impotence.
CA2338066A1 (fr) Traitement de la dyskinesie
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
EP1032556A4 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation
WO1998042650A3 (fr) Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose
WO1998026770A3 (fr) Utilisation locale d'agonistes opioïdes kappa dans le traitement de la douleur oculaire
CA2291160A1 (fr) Therapie combinatoire permettant de moduler la reponse sexuelle chez un patient
WO2002098362A3 (fr) Utilisation d'antagonistes rank dans le traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998545814

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA